Abstracts

Skip to Main Content

Order by

T1 - Circulating Tumor DNA (Ct DNA) as a Biomarker in High- Grade Gastroenteropancreatic Neuroendocrine Tumor

Published in 2020 Listed under Trials In Progress

S. Mukherjee, M. Choi, R. Ramirez, K. Attwood, R. Iyer

ABSTRACT ID: 116

T1 - Randomized Embolization Trial for Neuroendocrine Tumors (RETNET): First Safety Report

Published in 2019 Listed under Trials In Progress

Michael Soulen; Rony Avritscher; Ghassan El-Haddad; Nicholas Fidelman; Ricardo Garcia-Monaco; Sarah White; E. Paul Wileyto

Abstract ID: 15

T2 - A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Published in 2020 Listed under Trials In Progress

A. Chauhan, C. Kunos, R. El Khouli, J. Kolesar, B.M. Evers, M. Kidd, E. Kohn, L. Anthony

ABSTRACT ID: 155

T2 - Analyses of Patient Diaries in the NETTER-1 Study of 177Lu-DOTATATE vs. High Dose OCTREOTIDE in Progressive Midgut Neuroendocrine Tumors

Published in 2019 Listed under Trials In Progress

Jonathan Strosberg; Edward Wolin; Beth Chasen; Matthew Kulke; David Bushnell; Caplin Martin; Richard Baum; Timothy Hobday; Andrew Hendifar; Paola Santoro; Per Broberg; Arnaud Demange; Kjell Öberg; Philippe Ruszniewski; Eric Krenning

Abstract ID: 99

T3 - Cabozantinib in High Grade Neuroendocrine Neoplasm

Published in 2020 Listed under Trials In Progress

N. Trikalinos, D. Chatterjee, C. Hammill, E. Lu, K. Pedersen, H. Park, R. Suresh, A. Wang-Gillam, K.-H. Lim, N. Bagegni, R.C. Fields, B. Tan, P. Grierson, O. Aranha, K. Winter, M. Amin

ABSTRACT ID: 161

T3 - Impact of Baseline Liver Tumor Burden, Alkaline Phosphatase (ALP) Elevation,and Target Size Lesion on Therapeutic Effect of 177Lu-DOTATATE Treatment: Analysis of Progression Free Survival, and Safety in NETTER-1 Study

Published in 2019 Listed under Trials In Progress

Jonathan Strosberg; Pamela Kunz; Andrew Hendifar; James Yao; David Bushnell; Matthew Kulke; Richard Baum; Caplin Martin; Philippe Ruszniewski; Ebrahim Delpassand; Timothy Hobday; Chris Verslype; Al Benson; Berna Polack; Beilei He; Paola Santoro; Eric Krenning

Abstract ID: 115

T4 - A Pilot Study Assessing the Cognitive Profile in Neuroendocrine Tumour (NET) Patients with Carcinoid Syndrome (CS)

Published in 2019 Listed under Trials In Progress

Rachel Goodwin; Horia Marginean; Joanna Gotfrit; Tim Asmis; Michael Vickers; Stewart Longman; Janice Pasieka

Abstract ID: 130

T4 - Randomized, parallel arm, Phase II Study of Telotristat in combination with Lutetium Lu 177 Dotatate (Lutathera) in Well-Differentiated Neuroendocrine Tumors (NETs)

Published in 2020 Listed under Trials In Progress

A. Chauhan, S. Arnold, R. El Khouli, H. Weiss, L. Faul, L. Anthony

ABSTRACT ID: 188

T5 - 131I MIBG and 90Y DOTATOC in a Dosimetrically Determined Optimal Combination for Personalized Therapy of Selected Patients with Midgut Neuroendocrine Tumors: A First-In-Man Clinical Trial

Published in 2019 Listed under Trials In Progress

Kellie Bodeker; David Bushnell; Mark Madsen; Yusuf Menda; Kristin Gaimari-Varner; Stephen Graves; Thomas O'Dorisio; Joseph Dillon; Chandrikha Chandrasekharan

Abstract ID: 136

T6 - A Phase 2 Study Evaluating a Proprietary Amino Acid Based Medical Food (Enterade) in Patients with Quality of Life Limiting Diarrhea Due to Carcinoid Syndrome and Other Neuroendocrine Tumors

Published in 2019 Listed under Trials In Progress

Aman Chauhan; Mark Evers; Heidi Weiss; Val Adams; Jill Kolesar; Donald Cohen; Susanne Arnold; Lowell Anthony

Abstract ID: 152

T7 - A Pilot Phase 2 Study of S-1 and Temozolomide as Second-Line Treatment in Patients with Advanced or Metastatic Neuroendocrine Carcinoma

Published in 2019 Listed under Trials In Progress

Xin Wang; Zhirong Qi; Huangying Tan

Abstract ID: 165

[T10] Chauhan - NET RETREAT a CCTG SWOG Phase II Study of 177Lutetium Dotatate Retreatment vs Standard of Care in Metastatic GEPNET Patients

Published in 2025 Listed under Trials In Progress

[T11] Chauhan - A Phase 1 Trial of the Oncolytic Virus SVV 001 with Nivolumab and Ipilimumab in Patients with High Grade Neuroendocrine Neoplasms

Published in 2025 Listed under Trials In Progress

[T12] Pruitt (POSTER) - A Prospective Observational Study of GLP 1 and GLP 1 GIP Receptor Agonists in Patients with Well Differentiated Neuroendocrine Tumors

Published in 2025 Listed under Trials In Progress

[T12] Pruitt - A Prospective Observational Study of GLP 1 and GLP 1 GIP Receptor Agonists in Patients with Well Differentiated Neuroendocrine Tumors

Published in 2025 Listed under Trials In Progress

[T13] Ammabel Ynalvez - Stratification of Biochemical Response to Somatostatin Analogs in Carcinoid Syndrome Implications for Risk of Carcinoid Heart Disease

Published in 2025 Listed under Trials In Progress

[T14] Li - First in Human Study of a Novel Nonpeptide Drug Conjugate (CRN09682) in Patients With Somatostatin Receptor 2 Expressing Tumors

Published in 2025 Listed under Trials In Progress

[T15] Chauhan - ETCTN 10558 A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well Differentiated Somatostatin Receptor Positive Neuroendocrine Tumors

Published in 2025 Listed under Trials In Progress

[T1] Kunz (POSTER) - NETTER 3 [177Lu]Lu DOTA TATE in patients with newly diagnosed, Grade 1 2 (Ki 67 10%) advanced gastroenteropancreatic neuroendocrine tumors and high disease burden

Published in 2025 Listed under Trials In Progress

[T1] Kunz - NETTER 3 [177Lu]Lu DOTA TATE in patients with newly diagnosed, Grade 1 2 (Ki 67 10%) advanced gastroenteropancreatic neuroendocrine tumors and high disease burden

Published in 2025 Listed under Trials In Progress

[T2] Capdevila - STELLAR 311 A randomized phase 2 3 study of zanzalintinib versus everolimus in patients with previously treated advanced neuroendocrine tumors

Published in 2025 Listed under Trials In Progress

[T3] Chauhan - Obrixtamig (BI 764532) in relapsed refractory delta like ligand 3 (DLL3) high extrapulmonary neuroendocrine carcinoma Phase II DAREON® 5 dose expansion trial in progress

Published in 2025 Listed under Trials In Progress

[T4] Chauhan - CAREFNDR Phase 3, Randomized, Placebo Controlled Study of Paltusotine in Adults With Carcinoid Syndrome Due to Well Differentiated Neuroendocrine Tumors

Published in 2025 Listed under Trials In Progress

[T5] Mohamed - Trial in progress A Phase Ib II, Open label, Multi center Study of ZL 1310 in Participants with DLL3 positive Neuroendocrine Carcinomas (NECs) and other Selected Solid Tumors

Published in 2025 Listed under Trials In Progress

[T6] Soulen (POSTER) - Multicenter Phase 2 Trial of Yttrium 90 Radioembolization with Capecitabine Temozolomide for Grade 2 Liver Dominant Metastatic Neuroendocrine Tumors interim report

Published in 2025 Listed under Trials In Progress

[T6] Soulen - Multicenter Phase 2 Trial of Yttrium 90 Radioembolization with Capecitabine Temozolomide for Grade 2 Liver Dominant Metastatic Neuroendocrine Tumors interim report

Published in 2025 Listed under Trials In Progress

[T7] Narayan - Trial in Progress A Phase 2 Study of ONC206 in Patients with Advanced Pheochromocytoma and Paraganglioma

Published in 2025 Listed under Trials In Progress

[T8] Trikalinos - NCI 10479 A Phase I Dose Escalation Expansion Trial of Sunitinib Malate plus Lu 177 Dotatate in SSTR+ Pancreatic Neuroendocrine Tumors

Published in 2025 Listed under Trials In Progress

[T9] Hope - Alliance A021901 Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors

Published in 2025 Listed under Trials In Progress